Franklin Biotechnology Discovery Fund

Offshore Trusts

ManCo List

Funds by Name

Funds by Category

Word Search

FAQ

Franklin Biotechnology Discovery Fund

Franklin Biotechnology Discovery Fund

Franklin Templeton Investment Funds
	Franklin Biotechnology Discovery Fund
		News
		Regional Portfolio Structure(Semi-Annual Comparison)
		Sectorial Portfolio Structure(Semi-Annual Comparison)

Price

Ranking

Sector:	USA-Equity-Unclassified
Size:	(USD) 1 280 000 000

Sector Rank:	1 out of 3
(lump sum over 3 years to 30 Apr 2025)

Overall Rank:	155 out of 490
(lump sum over 3 years to 30 Apr 2025)

R20000 invested on 30 Apr 2022 was worth R28 616 at 30 Apr 2025
(12.68% annual compound return)

R5000 per month since 30 Apr 2022 was worth R197 428 at 30 Apr 2025
(5.92% annual return compounded monthly)

Please note that offshore fund performance figures are calculated from NAV prices (ie, equivalent to sell-to-sell) and therefore not directly comparable to domestic fund performance figures on this site.

Management
Evan McCulloch, CFA, Franklin Advisors Inc
Evan McCulloch is a vice president and portfolio manager for Franklin Advisers, Inc. He manages the Franklin Biotechnology Discovery Fund and the Franklin Biotechnology Fund. Mr McCulloch also specialises in research analysis of the health care industry; including pharmaceuticals, health care information systems/internet and health care providers. Mr McCulloch joined Franklin Templeton Investments in 1992 as a management trainee. He received a bachelor's degree in economics from the University of California at Berkeley. He is a Chartered Financial Analyst (CFA) and a member of the Association for Investment Management and Research (AIMR) and the Security Analysts of San Francisco (SAs/f).

Steve Kornfeld

Christopher Jay Lee

Wendy Lam

Akiva Felt

Focus and Objective
The investment objective of the fund is capital growth by investing in equity securities of biotechnology companies and discovery research firms mainly located in the USA substantial portion of its assets will be in smaller capitalisation companies (those with market capitalisation of less than USD2bn). For the fund's investment purposes, a biotechnology company is one that has at least 50% of its earnings derived from biotechnology activities, or at least 50% of its assets devoted to such activities based on the company's most recent fiscal year. Biotechnology activities are research, development, manufacture and distribution of various biotechnological or biomedical products, services and processes. This may include companies involved with genomics, genetic engineering and gene therapy. It also includes companies involved in the application and development of biotechnology in areas such as health care, pharmaceuticals and agriculture. To the extent that the fund invests in debt securities, it generally buys securities that are rated investment grade or unrated securities that it determines to be of comparable quality. Investment grade debt securities are rated in the top four ratings categories by independent ratings organisations such as Standard & Poor's Corporation or Moody's Investors Service Inc. The fund anticipates that under normal conditions, it will invest more of its assets in US securities than in those of any other single country although the fund may have more than 50% of its total assets in non-US securities. The manager may take a temporary defensive position when it believes the securities trading markets or the economies of countries where the fund invests are experiencing excessive volatility or prolonged general decline, or other adverse conditions exist. Under these circumstances, the fund may be unable to pursue its investment goal.

Technical Overview
Benchmark:	NASDAQ Biotechnology index
Administration Fee		Management fee (p.a.):	1.51%
Allows debit orders	No	Maximum Exit Fee
Annual Registrar Fee	0.20%	Minimum lump sum:	$5 000
Base currency:	USD	Minimum monthly:	$1 000
Broker Comm. Payable	Yes	Minimum Exit Fee
Custodian Fee		Number of holdings:	65
Domicile	Luxembourg	Original price:	USD 100.00
Exit fee charge:	No	Performance fee:
Formation date:	03 Apr 2000	Pricing system:	Forward
Is this fund a roll-up?	Yes	Promotional Fee

Top holdings on 31 Mar 2025

Share (Sector)	Value (USD)	% of fund
AMGEN (Healthcare)	99 968 000	7.81%
GILD.US ()	98 560 000	7.70%
VERTEXPHARM (Healthcare)	96 768 000	7.56%
REGENERONPHA (Healthcare)	68 480 000	5.35%
ASCENDIS (Pharmaceuticals and Biotechnology)	55 808 000	4.36%
JAZZPHARMA (Healthcare)	51 712 000	4.04%
PTC (Technology)	38 144 000	2.98%
TOTALS	509 440 000	39.80%